R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.

@article{Gang2012RCHOEP14IO,
  title={R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.},
  author={Anne Ortved Gang and Camilla Str\om and Michael Pedersen and Francesco D'amore and Lars Moller Pedersen and Anne Roslev Bukh and Bjarne Bach Pedersen and Machelle B Moeller and Leif Spange Mortensen and Ole V Gadeberg and Sten Ingeberg and Torben Mourits-Andersen and Stanislaw Pulczynski and P d Nully Brown},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 1},
  pages={147-53}
}
BACKGROUND Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further… CONTINUE READING